Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.19
RTIX's Cash to Debt is ranked lower than
52% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. RTIX: 0.19 )
RTIX' s 10-Year Cash to Debt Range
Min: 0.09   Max: No Debt
Current: 0.19

Equity to Asset 0.45
RTIX's Equity to Asset is ranked higher than
55% of the 447 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. RTIX: 0.45 )
RTIX' s 10-Year Equity to Asset Range
Min: 0.3   Max: 0.9
Current: 0.45

0.3
0.9
F-Score: 5
Z-Score: 1.01
M-Score: -2.63
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -2.89
RTIX's Operating margin (%) is ranked higher than
64% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 5.91 vs. RTIX: -2.89 )
RTIX' s 10-Year Operating margin (%) Range
Min: -76.65   Max: 10.76
Current: -2.89

-76.65
10.76
Net-margin (%) -2.27
RTIX's Net-margin (%) is ranked higher than
64% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 4.15 vs. RTIX: -2.27 )
RTIX' s 10-Year Net-margin (%) Range
Min: -77.87   Max: 8.42
Current: -2.27

-77.87
8.42
ROE (%) -3.40
RTIX's ROE (%) is ranked higher than
63% of the 445 Companies
in the Global Medical Devices industry.

( Industry Median: 5.20 vs. RTIX: -3.40 )
RTIX' s 10-Year ROE (%) Range
Min: -57.28   Max: 10.14
Current: -3.4

-57.28
10.14
ROA (%) -1.55
RTIX's ROA (%) is ranked higher than
65% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.77 vs. RTIX: -1.55 )
RTIX' s 10-Year ROA (%) Range
Min: -44.6   Max: 5.68
Current: -1.55

-44.6
5.68
ROC (Joel Greenblatt) (%) -3.69
RTIX's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 9.15 vs. RTIX: -3.69 )
RTIX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -92.51   Max: 32.86
Current: -3.69

-92.51
32.86
Revenue Growth (%) 5.00
RTIX's Revenue Growth (%) is ranked higher than
75% of the 341 Companies
in the Global Medical Devices industry.

( Industry Median: 5.00 vs. RTIX: 5.00 )
RTIX' s 10-Year Revenue Growth (%) Range
Min: -22.5   Max: 6.4
Current: 5

-22.5
6.4
EBITDA Growth (%) -49.00
RTIX's EBITDA Growth (%) is ranked higher than
54% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 1.60 vs. RTIX: -49.00 )
RTIX' s 10-Year EBITDA Growth (%) Range
Min: -49   Max: 128.9
Current: -49

-49
128.9
EPS Growth (%) -47.60
RTIX's EPS Growth (%) is ranked higher than
54% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. RTIX: -47.60 )
RTIX' s 10-Year EPS Growth (%) Range
Min: -47.6   Max: 223.1
Current: -47.6

-47.6
223.1
» RTIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

RTIX Guru Trades in Q4 2013

Chuck Royce 2,133,948 sh (+19.02%)
Jim Simons 349,000 sh (-38.6%)
» More
Q1 2014

RTIX Guru Trades in Q1 2014

Chuck Royce 2,262,948 sh (+6.05%)
Jim Simons 88,700 sh (-74.58%)
» More
Q2 2014

RTIX Guru Trades in Q2 2014

Chuck Royce 2,234,448 sh (-1.26%)
Jim Simons 26,600 sh (-70.01%)
» More
Q3 2014

RTIX Guru Trades in Q3 2014

Chuck Royce 1,907,948 sh (-14.61%)
Jim Simons 22,500 sh (-15.41%)
» More
» Details

Insider Trades

Latest Guru Trades with RTIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-03-31 Sold Out 0.03%$3.59 - $4.95 $ 5.3132%0
Joel Greenblatt 2012-12-31 Add 70.1%0.01%$4.06 - $4.61 $ 5.3124%135102
Mario Gabelli 2012-09-30 Sold Out $3.38 - $4.23 $ 5.3141%0
Ken Fisher 2012-09-30 Sold Out $3.38 - $4.23 $ 5.3141%0
Ken Fisher 2012-06-30 New Buy$3.46 - $3.88 $ 5.3147%13045
Joel Greenblatt 2012-03-31 Add 33.62%0.01%$3.45 - $4.47 $ 5.3144%73089
Joel Greenblatt 2011-12-31 New Buy0.03%$3.21 - $4.7 $ 5.3128%54700
Mario Gabelli 2011-12-31 Reduce -35.02%$3.21 - $4.7 $ 5.3128%28200
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.60
RTIX's P/B is ranked higher than
78% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.88 vs. RTIX: 2.60 )
RTIX' s 10-Year P/B Range
Min: 0.27   Max: 3.41
Current: 2.6

0.27
3.41
P/S 1.20
RTIX's P/S is ranked higher than
87% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.41 vs. RTIX: 1.20 )
RTIX' s 10-Year P/S Range
Min: 0.62   Max: 4.34
Current: 1.2

0.62
4.34
EV-to-EBIT -56.01
RTIX's EV-to-EBIT is ranked higher than
63% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 64.69 vs. RTIX: -56.01 )
RTIX' s 10-Year EV-to-EBIT Range
Min: -195.9   Max: 2390.3
Current: -56.01

-195.9
2390.3
Current Ratio 3.36
RTIX's Current Ratio is ranked higher than
77% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.79 vs. RTIX: 3.36 )
RTIX' s 10-Year Current Ratio Range
Min: 1   Max: 5.91
Current: 3.36

1
5.91
Quick Ratio 1.41
RTIX's Quick Ratio is ranked higher than
62% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.01 vs. RTIX: 1.41 )
RTIX' s 10-Year Quick Ratio Range
Min: 0.49   Max: 3.07
Current: 1.41

0.49
3.07

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 10.02
RTIX's Price/Tangible Book is ranked higher than
62% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 6.71 vs. RTIX: 10.02 )
RTIX' s 10-Year Price/Tangible Book Range
Min: 0.97   Max: 9.55
Current: 10.02

0.97
9.55
Price/DCF (Projected) 2.14
RTIX's Price/DCF (Projected) is ranked higher than
88% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. RTIX: 2.14 )
RTIX' s 10-Year Price/DCF (Projected) Range
Min: 0.82   Max: 36.25
Current: 2.14

0.82
36.25
Price/Median PS Value 0.84
RTIX's Price/Median PS Value is ranked higher than
87% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 1.20 vs. RTIX: 0.84 )
RTIX' s 10-Year Price/Median PS Value Range
Min: 0.61   Max: 2.88
Current: 0.84

0.61
2.88
Earnings Yield (Greenblatt) -1.80
RTIX's Earnings Yield (Greenblatt) is ranked higher than
64% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. RTIX: -1.80 )
RTIX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 8.8
Current: -1.8

0.1
8.8

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:RT2.Germany,
RTI Surgical Inc, formerly RTI Biologics, Inc., was incorporated in 1997 in Florida as a wholly-owned subsidiary of the University of Florida Tissue Bank. The Company process donated human musculoskeletal and other tissue, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera and dermal tissue, and bovine and porcine animal tissue in producing allograft and xenograft implants utilizing proprietary BIOCLEANSE, TUTOPLAST and CANCELLE SP sterilization processes and manufacture metal and synthetic implants for distribution to hospitals and surgeons. The Company process tissue at two facilities in Alachua, Florida and one facility in Neunkirchen, Germany, and manufacture metal and synthetic implants in Marquette, Michigan and Greenville, North Carolina. The Company distributes its implants and services in all 50 states and in over 45 countries. Its lines of business are comprised primarily of six categories: spine, sports medicine, surgical specialties, bone graft substitutes and general orthopedic, dental and ortho fixation. It has developed and utilized in the United States the patented BioCleanse tissue sterilization process, which is an automated, pharmaceutical grade chemical sterilization process for musculoskeletal bone and certain soft tissue. The TUTOPLAST tissue sterilization process utilizes solvent dehydration and chemical inactivation to remove blood, lipids and extraneous materials, and inactivate viruses and break down RNA and DNA into fragments not capable of replication and disease transmission while preserving the biological and mechanical properties. DBM-based pastes and putties are sterilized through the CANCELLE SP process, which is designed to preserve protein activity. The Company's competitors in the conventional allograft market include the Musculoskeletal Transplant Foundation ("MTF"), AlloSource, LifeCell, Inc., a subsidiary of Kinetic Concepts Inc. and LifeNet. Among its competitors in precision machined allograft are MTF, LifeNet and AlloSource. Other companies who process and distribute allograft pastes include Medtronic, AlloSource, Integra, Wright and MTF. Companies who process and distribute xenograft tissue include Synovis, LifeCell, Cook Surgical and Medtronic. The Company considers its competitors in the metal and synthetic markets to include Alphatec, Globus Medical, Inc. (Globus), NuVasive, Inc. (NuVasive) and Orthofix. The Company is subject to federal, state and foreign laws and regulations.
» More Articles for RTIX

Headlines

Articles On GuruFocus.com
Regeneration Technologies Inc. Reports Operating Results (10-Q) Nov 08 2010 
Weekly CFO Buys Highlight: Bank Mutual Corp., Heelys Inc., GenMark Diagnostics Inc., Regeneration Te Sep 19 2010 
Weekly CFO Buys Highlight: GNMK, RTIX, BKOR, PTEK, CLDX Sep 12 2010 
Regeneration Technologies Inc. Reports Operating Results (10-Q) Aug 09 2010 
Regeneration Technologies Inc. Reports Operating Results (10-Q) May 05 2010 
Regeneration Technologies Inc. Reports Operating Results (10-Q) Nov 02 2009 
Regeneration Technologies Inc. Reports Operating Results (10-Q) Aug 04 2009 
RTI Biologics Announces 2009 Second Quarter Results Jul 30 2009 
Regeneration Technologies Inc. Reports Operating Results (10-Q) May 02 2009 
RTI Biologics Announces 2008 Fourth Quarter Earnings and Year End Earnings and Conference Call Feb 11 2009 

More From Other Websites
RTI SURGICAL, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD... Dec 15 2014
RTI Surgical Announces Retirement of Thomas F. Rose Dec 15 2014
RTI Surgical™ Hosts Winter Biologics Spine Symposium Dec 12 2014
RTI Surgical Announces Online Publication of Study Highlighting nanOss Advanced Bone Graft... Nov 12 2014
10-Q for RTI Surgical, Inc. Nov 05 2014
RTI SURGICAL, INC. Files SEC form 10-Q, Quarterly Report Nov 03 2014
RTI Surgical beats Street 3Q forecasts Oct 30 2014
RTI Surgical beats Street 3Q forecasts Oct 30 2014
RTI SURGICAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Oct 30 2014
RTI Surgical™ Announces 2014 Third Quarter Results Oct 30 2014
Q3 2014 RTI Surgical Inc Earnings Release - Before Market Open Oct 30 2014
RTI Surgical (RTIX) Jumps: Stock Moves 12.6% Higher Oct 24 2014
RTI SURGICAL, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD... Oct 23 2014
RTI Surgical™ Schedules 2014 Third Quarter Earnings Conference Call for October 30, 2014 Oct 23 2014
Shirley A. Weis Joins RTI Surgical Board of Directors Oct 22 2014
Shirley A. Weis Joins RTI Surgical Board of Directors Oct 22 2014
RTI Surgical™ Receives Letter From FDA on map3® Cellular Allogeneic Bone Graft Oct 09 2014
RTI Surgical™ Hosts Surgeon Education Symposium Highlighting the Future of Spine Surgery Oct 07 2014
Accuray Falls despite Positive TomoTherapy Data Sep 23 2014
Thoratec Corp. (THOR) In Focus: Stock Adds 6.1% in Session Sep 23 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK